The orphan nuclear receptor pregnane X receptor (PXR) plays an important role in the detoxification of foreign and endogenous chemicals, including bile acids. PXR promotes bile acid elimination by activating bile acid-detoxifying enzymes and transporters. Certain bile acids are known to promote colonic carcinogenesis by inducing colon cancer cell apoptosis. However, whether and how PXR plays a role in colon cancer apoptosis has not been reported. In this study, we showed that activation of PXR by genetic (using a constitutively activated PXR) or pharmacological (using PXR agonist rifampicin) means protected the PXR-overexpressing colon cancer HCT116 cells from deoxycholic acidinduced apoptosis. Interestingly, activation of PXR also protected HCT116 cells from adriamycin-induced cell death, suggesting that the antiapoptotic effect of PXR was not bile acid specific. Moreover, the antiapoptotic effect of PXR in HCT116 cells appeared to be independent of xenobiotic enzyme 
C
OLON CANCER IS the second most common fatal malignancy in the Western world. The United States is one of the countries with the highest incidence of colon cancer (1) . Numerous factors have been implicated in the etiology of colon cancer. These include, but are not limited to, genetic abnormalities, such as the tumor suppressor gene adenomatous polyposis coli (APC) (2) and cyclooxygenase 2 (COX-2) (3, 4); and environmental factors, such as high-fat Western-style diet (5, 6) and toxic bile acids (7, 8) .
Bile acids are metabolic derivatives of cholesterol that are synthesized in the liver and excreted into the small intestine, where they aid in the absorption of dietary fats and lipophilic nutrients (9, 10) . Most bile acids are reabsorbed in the intestine. However, a small quantity remains unabsorbed and passes into the colon where they are converted to secondary bile acids, such as deoxycholic acid (DCA) and lithocholic acid (LCA), by enteric bacteria. Both epidemiological and animal studies have suggested that bile acids can function as endogenous colon tumor promoters (7, 8) . In addition to the direct effect of bile acids as colon cancer promoters, increased secretion of bile acids and exposure of the colorectal epithelium to fecal bile acids have been thought to be important contributing factors for the colon cancer-causing effect of high-fat Western diet (11, 12) .
Bile acid-induced colon epithelial apoptosis is believed to be an important mechanism for its participation in colon cancer development (13, 14) . It was believed that the ability of bile acids to induce apoptosis in colon epithelium can render selective survival and repopulation of apoptosis-resistant cells over a longterm exposure to bile acids, which ultimately lead to colonic carcinogenesis. Consistent with this notion, patients with a history of colon cancer or familial adenomatous polyposis were found to have a reduced ability to undergo induced apoptosis compared with individuals with no history of colon neoplasia (13) . The hydrophobic DCA is one of the best-described apoptotic bile acids, but the mechanism of DCA-induced apoptosis has been a subject of debate. In human colon cancer cells, DCA has been shown to promote carcinogenesis by stimulating proteosome-mediated p53 protein degradation (15) . The effects of DCA on apoptosis were subjected to modulation by the mitogen-activated kinases, bcl-2, and protein kinase C (16) (17) (18) . In certain colon cancer cells, such as the HCT116 cells, DCA can induce cytochrome c release and caspase activation, leading to apoptosis (19) .
Pregnane X receptor (PXR) was isolated as a xenobiotic receptor that regulates the expression of drug metabolizing/detoxifying enzymes and transporters (for reviews, see Refs. 20 and 21) . PXR has been shown to be important in xeno-and endobiotic responses, including bile acid detoxification. PXR promotes bile acid detoxification by activating bile acid-metabolizing enzymes and transporters. These include the phase I enzyme cytochrome P450 3A (CYP3A) (22, 23) , phase II enzyme sulfotransferase 2A9 (SULT2A9) (24) , and drug transporter multidrug resistance-associated protein 2 (25) . Having known the role of PXR in bile acid detoxification, it is unclear whether activation of PXR can prevent colon cancer cells from bile acid-induced apoptosis, and if so, whether the activation of bile acid-detoxifying enzymes is necessary for this antiapoptotic effect.
In this report, we showed that genetic or pharmacological activation of PXR was sufficient to inhibit DCA-, adriamycin-, and staurosporine-induced apoptosis in human colon cancer cells. Gene expression analysis showed that the antiapoptotic effect of PXR was associated with the regulation of multiple apoptosis-related genes. The antiapoptotic effect of PXR was also observed in normal mouse colon epithelium.
RESULTS

Creation of Colon Cancer Stable Cell Lines that Express the Wild-Type or Activated PXR
A retroviral transfection method (26) was used to create colon cancer HCT116 cells that express the wildtype human PXR or the constitutively activated PXR (VP-PXR). VP-PXR was created by fusing the viral protein 16 (VP16) activation domain of the herpes simplex virus to the amino terminus of human PXR (21) . The expression of transduced PXR and VP-PXR mRNA was confirmed by real-time RT-PCR analysis using PXR-specific probes. As shown in Fig. 1 , the vector-transfected HCT116 cells had a low level expression of endogenous PXR. In contrast, PXR mRNA expression was readily detectable in PXR and VP-PXR-transfected HCT116 cells (Fig. 1A) . We have previously created colon cancer LS180 cells stably transfected with vector or VP-PXR using the same retroviral transfection method (26) . The expression of transduced VP-PXR mRNA in LS180-VP-PXR cells was also confirmed by real-time PCR analysis (Fig. 1B) . Human liver RNA isolated from three cases of primary human hepatocytes was included as a positive control for PXR expression.
Genetic or Pharmacological Activation of PXR Inhibited DCA-Induced HCT116 Cell Apoptosis
DCA is known to induce apoptosis in HCT116 cells (15) (16) (17) (18) . Flow cytometry was first used to investigate the effect of PXR activation on DCA-induced HCT116 cell apoptosis. In this experiment, HCT116-Vector and HCT116-VP-PXR cells were treated with DCA over a time course before harvesting for flow cytometry analysis. Our preliminary study showed that HCT116 apoptosis was DCA dose dependent, and nearly 50% apoptosis was achieved after treatment with 250 M DCA for 4 h (data not shown). We therefore chose the 250 M dose in subsequent experiments. Results in Fig. 2A showed that, after a 4-h treatment, 42% Vector cells became apoptotic, which was evidenced by the enrichment of the sub-G1 population in cell cycle profile. In sharp contrast, the percentage of apoptotic VP-PXR cells (4%) was near the basal level. At 12-24 h after treatment, 84-90% of the A, Real-time PCR analysis on HCT116 cells stably transfected with vector, wild-type human PXR, or activated VP-PXR. B, Real-time PCR analysis on LS180 cells stably transfected with vector, or activated VP-PXR. Results are presented as averages and SD from three independent clones for each cell line. Human hepatocytes from three patients (all Caucasians, including a 45-yr-old male, a 67-yr-old female, and an 84-yr-old male) were included as a control. Vector cells were apoptotic, compared with 8.9-17% seen in the VP-PXR cells (Fig. 2A) . The antiapoptotic effect was also seen in HCT116-PXR cells treated with the human PXR agonist rifampicin (RIF). In this experiment, RIF treatment (10 mM) started 24 h before the DCA exposure and continued until the completion of the experiment. As shown in Fig. 2B , treatment with RIF caused a significant inhibition of DCA-induced apoptosis at 12 h, although the inhibitory effect of PXR ligand was not as dramatic as that observed in the VP-PXR cells. The quantification of DCA-induced apoptosis and the effect of PXR activation were summarized in Fig. 2 , C and D. A similar pattern of PXR effect was observed when additional individual clones or pooled clones were used (see Fig. 2 legend for details) .
The antiapoptotic effect of PXR was confirmed by TUNEL (terminal deoxynucleotide transferase-mediated dUTP nick end labeling) and caspase 3 activity assays. In the TUNEL assay, cells were treated with 250 M DCA for 3 h before fixation and TUNEL staining. As shown in Fig. 2E and results summarized in Fig.  2F , approximately 35% of Vector cells were positive for TUNEL staining, whereas only 3% of VP-PXR cells were stained positive after the same DCA treatment. A modest but significant inhibition of DCA-induced TUNEL staining was also seen in HCT116-PXR cells treated with RIF for 24 h before DCA exposure (Fig. 2 , E and F).
Caspase 3 is a downstream effector caspase the activation of which indicates the occurrence of apoptosis. A previous report showed that treatment with DCA induced caspase 3 activation in HCT116 cells, and the general caspase inhibitor Z-Val-Ala-Asp-fmk (Z-VAD-FMK) completely inhibited DCA-induced apoptosis (19) . Results in Fig. 2G showed that treatment with DCA induced caspase 3 activation in Vector cells in a time-dependent manner, consistent with the previous report (19) . Caspase 3 activation can be seen as early as 1 h of DCA treatment. At 24 h, caspase 3 activation was 8-fold that of the untreated cells, but this activation was completely inhibited by Z-VAD-FMK. In contrast, little caspase 3 activation was seen in DCA-treated VP-PXR cells. A similar inhibition of DCA-induced caspase 3 activation was also seen in PXR cells treated with RIF for 24 h before DCA exposure (Fig. 2G) . Interestingly, DCA was not able to induce apoptosis in either vector-or VP-PXR-transfected LS180 cells (data not shown), suggesting that the DCA effect was cell type specific.
The Antiapoptotic Effect of PXR in HCT116 Cells Was Not Bile Acid Specific and May Not Rely on the Activation of Bile Acid-Detoxifying Enzymes
To determine whether the antiapoptotic effect of PXR was bile acid specific, we exposed cells to 0.5 mg/ml adriamycin, another agent known to induce apoptosis in HCT116 cells at this dose range (27) , for 24 h. Both flow cytometry (Fig. 3 , A-D) and caspase 3 activation (Fig. 3E ) assays revealed that VP-PXR or RIF-treated PXR cells showed protection from adriamycin-induced apoptosis. Of note, adriamycin (0.5 mg/ml) appeared to be less effective than DCA (250 M) in inducing apoptosis in HCT116 cells. Adriamycin treatment for 24 h resulted in an apoptotic rate of 24% in the Vector cells (Fig. 3A) , compared with the rate of 90% in DCA-treated counterparts ( Fig. 2A) . Nevertheless, the resistance to adriamycin-induced apoptosis suggested that the antiapoptotic effect of PXR was not bile acid specific.
Although PXR is known to promote bile acid detoxification, the apoptotic resistance to the non-bile acid adriamycin suggested that the antiapoptotic effect of PXR may not rely on the activation of bile acid-detoxifying enzymes. To test this hypothesis, the expression of major bile acid-metabolizing enzymes, including CYP3A4, glucuronosyltransferase 1A1 (UGT1A1), and SULT2A1, was evaluated by real-time RT-PCR. Compared with LS180-Vector, LS180-VP-PXR, and primary human hepatocytes, the expression of both CYP3A4 and UGT1A1 was much lower and the expression of SULT2A1 was undetectable in either vector or VP-PXR-transfected HCT116 cells (Fig. 3, F 
-H).
The low basal and PXR-inducible expression of major bile acid-metabolizing enzymes suggested that the antiapoptotic effect of PXR in HCT116 cells may not have resulted from the activation of bile acid metabolism.
Pharmacological Activation of Endogenous PXR in LS180 Cells Inhibited Staurosporine-Induced Apoptosis
Having demonstrated the antiapoptotic effect of PXR in PXR-overexpressing HCT116 cells, we went on to determine whether activation of the endogenous PXR in colon cancer cells is sufficient to inhibit apoptosis. For this purpose, we used the parent LS180 cells, which are known to express PXR, and treatment with RIF activated PXR target gene expression in these cells (28, 29) . Staurosporine was chosen as the apoptotic agent because it has been used to show the antiapoptotic effect of PXR in hepatocytes (30) , and our preliminary results showed that LS180 cells were sensitive to this drug. As shown in Fig. 4 , treatment with RIF (10 M) was sufficient to inhibit staurosporine (200 nM)-induced apoptosis as measured by flow cytometry (Fig. 4, A and B) or TUNEL assay (Fig. 4C) . In this experiment, RIF treatment started 24 h before staurosporine exposure (48 h) and continued until the completion of the experiment. RIF was also able to inhibit adriamycin-induced apoptosis in LS180 cells (data not shown), again suggesting that the antiapoptotic effect of PXR was not drug specific.
Molecular Mechanism by Which PXR Inhibited DCA-Induced Apoptosis in HCT116 Cells
To understand the molecular mechanism by which PXR inhibited apoptosis, we profiled the expression of apoptosis-related genes by using apoptosis pathwayfocused oligonucleotide SuperArray from SuperArray Bioscience (Frederick, MD). In this experiment, total RNA was extracted from the HCT116-Vector and HCT116-VP-PXR cells treated with DCA (250 M) or mock treated for 2 h and subjected to SuperArray analysis. The means of nine housekeeping genes were used to normalize the hybridization signals. Results in Fig. 5A highlight several genes the expression of which was dramatically altered in VP-PXR cells, and the relative fold expressions are summarized in Table 1 . Most notable changes were seen in the DCA-treated VP-PXR cells. These included the up-regulation of several antiapoptotic genes, including Bcl-2-associated athanogene 3 (BAG3, also known as CAIR-1) (31), baculoviral inhibitor of apoptosis repeat-containing protein 2 (BIRC2) (32) , and myeloid cell leukemia sequence 1 (MCL-1) (33), whereas the expression of proapoptotic genes, including Bcl2-antagonist/killer 1 (BAK1) (34) and tumor protein 53 (TP53, or p53) (35) was down-regulated in the same cells. The SuperArray results were confirmed by real-time RT-PCR analysis (Fig. 5B) . Interestingly, activation of PXR alone, in the absence of DCA treatment, significantly suppressed the expression of BIRC2 and induced the expression of BAK1, but VP-PXR had little effect on the basal expression of BAG3, MCL1, and TP53. A similar pattern of apoptotic and antiapoptotic gene regulation was observed in DCA-and RIF-treated HCT116-PXR cells (Fig. 5C ). The inhibition of TP53 protein expression in DCA-treated HCT116-VP-PXR cells was also confirmed by Western blot analysis (Fig. 5D) . The activation of antiapoptotic genes and inhibition of proapoptotic genes provided a plausible mechanism for the antiapoptotic effect of PXR.
We also evaluated the expression of several other apoptosis-related genes, including Bcl-2, Bcl-xL, growth arrest-and DNA damage-inducible gene 153 (GADD153), TR3, and MDM-2. Activation of Bcl-2 and Bcl-xL has been implicated in PXR-mediated protec- tion from staurosporine-induced apoptosis in hepatocytes (30) . GADD153 is known to be induced in DCAtreated HCT116 cells (36) . TR3 (also known as Nur77, NGFI-B, TIS1, or NAK-1) is an orphan receptor the expression of which can be rapidly induced in various apoptotic cancer cells (37, 38) . Activation of MDM-2 by the constitutive androstane receptor (CAR) has been associated with the effect of CAR in promoting cell proliferation and inhibiting p53-dependent apoptosis in the liver (39) . We found that, compared with vector-transfected cells, the expression of Bcl-2 and Bcl-xL was similarly induced in DCA-treated VP-PXR cells, although the basal expression of these two genes was modestly elevated in the VP-PXR cells (Fig.  5E, left panel) . These results suggested that Bcl-2 and Bcl-xL induction per se may not account for the protective effect of PXR. The basal expression of GADD153 and TR3 was not significantly altered in the VP-PXR cells, and the expression of both genes was dramatically and similarly induced in DCA-treated Vector or VP-PXR cells (Fig. 5E, right panel) . The expression of MDM-2 was unchanged between the Vector and VP-PXR cells regardless of DCA treatment (data not shown), suggesting that the antiapoptotic mechanism of PXR may differ from that of CAR.
Activation of PXR Inhibited Bile Acid-Induced Apoptosis and Sensitized Mice to Dimethylhydrazine (DMH)-Induced Colonic Carcinogenesis in Vivo
We next evaluate whether PXR also has an anti-apoptotic effect in vivo. For this purpose, we used the fatty acid-binding protein (FABP)-VP-PXR transgenic mice that express the activated VP-PXR in the intestinal tracts, including the colon, under the control of FABP gene promoter (26) . In this experiment, wild-type and VP-PXR transgenic mice were challenged with the toxic secondary bile acid LCA by enema for 5 wk. Mice were then killed and colon tissues were harvested for TUNEL assay for detection of apoptotic cells. LCA administration in the colon is known to promote apoptosis (40) . As expected, TUNEL assay showed that the percentage of apoptotic cells increased from 0.6% to 1.7% (ϳ2.5-fold increase) in wild-type mice after LCA treatment (Fig. 5A) . In contrast, the apoptotic rate in LCA-treated transgenic mice (1.1%) was significantly lower than their wild-type counterparts (Fig. 6A) , suggesting that PXR also has an antiapoptotic effect in vivo.
To determine whether activation of PXR affects colonic carcinogenesis, wild-type and VP-PXR transgenic mice were subjected to DMH treatment (10 mg/ kg) for 18 wk, an established model of chemical colonic carcinogenesis (41) . DMH-treated mice were killed, and all of the colon tissues were dissected and inspected for tumor formation 12 wk after the last dose of DMH. Carcinogenesis was scored by the appearance of tumor nodules. We found that 44% (four of nine mice) of the wild-type mice developed tumors, an incidence close to what has been reported (41) . In contrast, 81% (13 of 16 mice) of the VP-PXR transgenic mice developed tumors. Figure 6B shows representative tumor-free and tumor-bearing colon tissues from the wild-type and transgenic mice. The tumor identify of the nodules was confirmed by paraffin section and hematoxylin and eosin staining (data not shown).
When the expression of apoptosis-related genes was measured in DMH-treated mice, we found that the expression of none of the 11 genes analyzed in human colon cancer cells (Fig. 5 ) was significantly altered in the transgenic group when both tumor-bearing and tumor-free mice (Fig. 6C) or only the tumor-bearing mice (data not shown) were included in the analysis. Interestingly, when only the tumor-free mice were included in the analysis, the expression of Bcl-xL, an antiapoptotic survival protein, was found to be significantly higher in the transgenic group (Fig. 6D) , consistent with an earlier report in primary hepatocytes (30) .
DISCUSSION
In this study, we found that PXR can protect human colon cancer HCT116 cells from DCA-and adriamycin-induced apoptosis. The antiapoptotic effect was also observed in PXR transgenic mice treated with LCA, a known apoptotic bile acid in vivo (40) . Subsequent gene expression analysis showed that the antiapoptotic effect of PXR in HCT116 cells was associated with the activation of multiple antiapoptotic genes and inhibition of several proapoptotic genes.
The antiapoptotic effect of PXR was first observed and SuperArray analyses were performed on the VP-PXR-overexpressing cells. VP-PXR represents a gain of function model of receptor activation. Although the receptor is constitutively activated, the target gene regulation and the implication of this regulation in apoptosis have been shown to be consistent with those of the wild-type receptors in response to ligand treatments. The same strategy has been successfully used by us and others to study nuclear receptor functions both in vitro and in transgenic mice (21, 26, (42) (43) (44) (45) . In the current study, the VP-PXR effect on apoptosis and associated gene regulation was confirmed in ligand-treated wildtype PXR-expressing HCT116 cells, although the ligand effects were overall less dramatic. Moreover, treatment with RIF in LS180 cells, a cell line known to express endogenous PXR, was shown to inhibit staurosporineinduced apoptosis.
Although PXR and CAR were isolated as "xenobiotic receptors" postulated to regulate the expression of drug-metabolizing enzymes and transporters, emerging evidence has pointed to a potential role of these receptors in other cellular functions, including apoptosis. PXR was shown to protect from staurosporineinduced apoptosis in hepatocytes, which involved the activation of antiapoptotic genes Bcl-2 and Bcl-xL (30) . In HCT116 cells, Bcl-2 and Bcl-xL were efficiently induced in both vector-and VP-PXR-transfected cells upon DCA treatment, suggesting that activation of Bcl-2 and Bcl-xL alone may not account for the antiapoptotic effect of PXR. CAR has been shown to suppress p53-mediated apoptosis in hepatocytes by directly regulating MDM-2 (39). In our study, activation of PXR had no effect on MDM-2 expression (data not shown), suggesting that the mechanism by which PXR suppresses apoptosis is different from that of CAR.
PXR has been shown to promote bile acid detoxification by activating bile acid-metabolizing enzymes, such as CYP3A, SULT2A, and UGT1A1 (22, 23, 46, 47) . However, several lines of evidence suggested that the antiapoptotic effect of PXR may not rely on its activation of bile acid-detoxifying enzymes. First, the effect was not bile acid specific, because activation of PXR also prevented adriamycin-and staurosporineinduced apoptosis. Moreover, compared with other colon cancer cells and primary hepatocytes, HCT116 cells had little basal and PXR-inducible expression of major bile acid-detoxifying enzymes. Interestingly, LS180 cells that have relatively high basal and inducible expression of CYP3A4 and UGT1A1 (Fig. 3, F and G), were resistant to DCA-induced apoptosis even in the absence of PXR activation (data not shown). However, LS180 cells were sensitive to staurosporine- (Fig.  4) and adriamycin (data not shown)-induced apoptosis, and treatment with the PXR agonist RIF was antiapoptotic in LS180 cells. The mechanism for cell type specificity of bile acid-induced apoptosis in colon cancer cells remains to be defined.
Our SuperArray and real-time PCR analysis showed that the antiapoptotic effect of PXR was associated with altered expression of multiple apoptosis-related genes. These include the up-regulation of anti-apoptotic genes BAG3, BIRC2, and MCL-1, and down-regulation of proapoptotic genes BAK1 and TP53. BAG3 was identified as a Bcl-2 interacting protein. It was shown that BAG3 itself had only weak antiapoptotic activity, but was synergistic with Bcl-2 in preventing Bax-induced and Fasmediated apoptosis (48) . Interestingly, Bcl-2 was also induced in DCA-treated VP-PXR cells (Fig. 4D) . BIRC2 belongs to the inhibitor of apoptosis family of antiapoptotic proteins. Inhibitors of apoptosis inhibit apoptosis by inhibiting the activation of procaspase, as well as directly inhibiting activated caspases, such as caspases 3 and 7 (49) . Some BIRC family members were found to be highly expressed in apoptosis-resistant colon cancer cell lines, indicating that BIRC may play a role in the apoptotic resistance in colon cancer cells (49) . MCL-1, a Bcl-2 family member, plays a critical role in the survival of cancer cells. Depletion of MCL-1 via antisense oligodeoxynucleotides triggered apoptosis in cancer cells (50) . It remains to be determined whether or not BAG3, BIRC2, and MCL-1 are direct transcriptional targets of PXR. Preliminary bioinformatic analysis on the approximate 2-to 3-kb 5Ј-regulatory sequences of these genes failed to identify conserved PXR response elements. It is also important to note that activation of PXR did not induce the basal expression of these antiapoptotic genes, but rather increased their bile acidresponsive expression. The mechanism for this apoptotic challenge-specific gene regulation remains to be determined. Nevertheless, the up-regulation of antiapoptotic genes provides a plausible explanation for the antiapoptotic effect of PXR.
Among genes down-regulated in PXR-activated and DCA-treated HCT116 cells, TP53/p53 is an important tumor suppressor gene. In the presence of DNA damages, TP53 can be activated and promote cell cycle arrest and allow cells to repair the damaged DNA. If DNA damages are beyond repair, TP53 will then promote cells to apoptosis (35, (51) (52) . DCA has been shown to stimulate proteasome-mediated p53/TP53 degradation (15) . Our results suggested that DCA also suppresses TP53 expression at the transcriptional level. BAK1 is another proapoptotic gene. In healthy cells, BAK1 is kept inactive by association with the antiapoptotic MCL-1. In the presence of apoptotic stimuli, such as UV DNA damage and oncogene activation, MCL-1 will be eliminated by proteasome-mediated degradation, thereby unleashing BAK1 to promote apoptosis (53) (54) (55) . Interestingly, BAK1 is one of few apoptotic genes the expression of which was robustly induced by PXR activation in the absence of DCA treatment, but its expression in the same cells was dramatically suppressed upon DCA exposure (Fig. 5, A-C) . The significance of PXR-induced higher BAK1 basal expression in the antiapoptotic phenotype of PXR activation is unknown. Nevertheless, the down-regulation of TP53 and BAK1 may have also contributed to the DCA resistance.
The antiapoptotic role of PXR was also observed in the colon of transgenic mice that express the constitutively activated PXR in this tissue. The transgenic mice showed resistance to LCA-induced apoptosis. The sensitization of transgenic mice to DMH-induced colonic carcinogenesis was also consistent with the antiapoptotic role of PXR. The gene regulation responsible for the antiapoptotic effect of PXR in vivo is not completely understood at present. In the LCA model, the mRNA expression pattern of Bag-3, Birc2, Mcl1, Bak1, and Tp53 was not significantly altered in the colon of transgenic mice, regardless of the LCA treatment (data not shown). In the DMH model, the expression of 11 apoptosis-related genes analyzed in human colon cancer cells (Fig. 5) was not significantly altered in the transgenic group when both tumor-bearing and tumor-free mice were included in the analysis (Fig.  6C) . However, when only the tumor-free mice were included in the analysis, the expression of the antiapoptotic gene Bcl-xL was significantly increased in the transgenic group (Fig. 6D) , consistent with an earlier report in primary hepatocytes (30) . The discrepancies between the human cells and mouse tissues could be due to combined factors of apoptotic agents used, species specificity of gene regulation, as well as cancerous cells vs. normal colon epithelium.
In summary, our results have established an antiapoptotic role of PXR in colon cancer cells and normal colon epithelium. Moreover, we showed that the antiapoptotic effect of PXR in colon cancer cells was not bile acid specific and may not involved the much anticipated regulation of bile acid-metabolizing enzymes. The antiapoptotic effect of PXR does not seem to be cell type specific, because similar effects of PXR on apoptosis were seen in hepatocytes (30) and human endometrial cancer cells (57) . Future studies are necessary to determine the in vivo relevance of PXR-mediated antiapoptosis in human colorectal carcinogenesis.
MATERIALS AND METHODS
Creation of PXR-Expressing Cell Lines
HCT116 cells were maintained in McCoy's 5A medium supplemented with 10% fetal bovine serum. Stable PXR-expressing HCT116 cells were generated by a retroviral transfection method as we have described previously (26) . In brief, cDNAs of the wild-type human PXR or constitutively activated VP-PXR were cloned into the pBabe retroviral vector (26) . VP-PXR was created by fusing the VP16 activation domain of the herpes simplex virus to the amino terminus of human PXR (21) . For retroviral production, pBabe vectors of PXR, VP-PXR, or the empty vector were transfected into Phoenix-Ampho helper-free retroviral-producing cells using Lipofectamine 2000 from Invitrogen (Carlsbad, CA). Cell culture medium that contained the retrovirus were harvested 48 h after transfection and used to infect HCT116 cells. Cells were replaced with medium supplemented with puromycin (2-4 mg/ml) 24 h after infection and selected for 2-3 wk before clone pick and expansion. The creation of LS180-VP-PXR stable cells was previously described (26) .
Induction of Apoptosis
Cells were seeded onto six-well tissue culture plates and let grow to subconfluency. Cells were then replaced with fresh medium containing DCA (250 M), adriamycin (0.5 mg/ml), or staurosporine (200 nM) for various amounts of time to induce apoptosis.
Flow Cytometry
Both floating cells in the medium and adherent cells were collected after apoptotic induction. Cells were then washed with PBS and trypsinized to achieve single cell suspensions. Cells were then stained with propidium iodide and analyzed using an EPICS XL-MCL flow cytometer at the University of Pittsburgh Cancer Institute. Quantitation of the apoptotic sub-G1 portions was performed with WinMD1 Software (http://facs.scripps.edu/software.html).
TUNEL Assay
For the HCT116 cell TUNEL assay, cells were air dried and fixed in 4% paraformaldehyde for 1 h at room temperature. TUNEL assay was performed with the In Situ Cell Death Kit, peroxidase (catalog no. 11684817910) from Roche (Indianapolis, IN), following the manufacturer's instruction. In brief, fixed cells were rinsed in PBS, blocked, and permeabilized. TUNEL reaction mixture was then added to the cells and incubated at 37 C for 1 h. Apoptotic signals were converted with peroxidase and stained with 3,3Ј-diaminobenzidine tetrahydrochloride. For TUNEL assay in colon tissues, In Situ Cell Death Kit (catalog no. 11684815910) from Roche was used. Paraffin-embedded tissue sections were dewaxed and rehydrated with a graded series of ethanol. Sections were treated with proteinase K and then incubated with TUNEL reaction mixture. Apoptotic cells were detected and scored under fluorescence microscope with 4Ј,6-diamidino-2-phenylindole counter staining. For the LS180 cell TUNEL assay, apoptotic cells were detected and scored by flow cytometry.
Measurement of Caspase 3 Activity
Caspase 3 activity was determined by using the Caspase Assay Kit (catalog no. 0509011819) from CHEMICON (Temecula, CA), following the manufacturer's instruction. In brief, cells were collected, washed in PBS, and lysed in lysis buffer. Nuclei were removed by centrifugation, and the cytosolic fractions were added into caspase assay buffer. After reaction, the absorbance at 405 nm was measured with an ELISA plate reader. The caspase inhibitor Z-VAD-FMK was included in the Caspase Assay Kit and was applied to the cell culture at the concentration of 10 mM.
SuperArray Analysis
Total RNAs were isolated using TRIZOL reagent from Invitrogen. RNAs were then treated with DNase I (1 U/ml) to eliminate possible genomic DNA contamination. The absence of DNA contamination was confirmed by PCR for 35 cycles with primers of GAPDH (data not shown). The apoptosis pathwayfocused oligonucleotide SuperArray membranes (catalog no. OHS012) and related reagents were purchased from SuperArray Bioscience. cRNA synthesis, labeling, and hybridization were performed following the manufacturer's instruction. Hybridization signals were detected with chemiluminescent detection kit. Image analysis and data acquisition were performed using the web-based integrated GEArray Expression Analysis Suite provided by SuperArray Bioscience. We used the means of nine housekeeping genes to normalize the intensity of the signals.
Real-Time RT-PCR
Total RNAs were isolated using TRIZOL reagent. Real-time PCR using the SYBR-green reagent was performed with the ABI 7300 Real-Time PCR System as we have previously described (56) . Sequences of the CYBR-green oligonucleotide probes are available upon request.
LCA Animal Experiments and DMH Model of Colonic Carcinogenesis
Age-matched 8-to 10-wk-old wild-type and FABP-VP-hPXR transgenic mice (26) were used. Mice were housed in a pathogen-free animal facility under a standard 12-h light, 12-h dark cycle with free access to water and food. For treatment, mice received 1 ml of 5 mM LCA enema or vehicle (corn oil) twice a day for 5 wk before being killed. Colon tissues were harvested and processed for paraffin sections and stained for TUNEL or hematoxylin and eosin. The DMH model was carried out essentially as described by Narisawa and colleagues (41) . In brief, 8-wk-old mice were subjected to 18 weekly ip injections of DMH (from Sigma Chemical Co., St. Louis, MO) at the dose of 10 mg/kg body weight. Mice were killed 12 wk after the last dose of DMH, and the entire colon tissues were dissected and inspected for tumor nodules. The use of mice in this study has complied with all relevant federal guidelines and institutional policies.
Western Blot Analysis
Cells from 60-mm culture dishes were lysed with 100 ml Cell Lysis Buffer (catalog no. E153A) from Promega Corp. (Mad-ison, WI). Lysates were resolved by 12% SDS-PAGE gel, and proteins were then transferred to polyvinylidinedifluoride membrane. Membranes were blocked with 5% nonfat dry milk in PBS-Tween 20 at room temperature for 1 h. Immunoblotting of primary antibodies was performed at 4 C overnight. The following day, membranes were washed and incubated with secondary antibody, and signals were detected with enhanced chemiluminescence reagent (catalog no. RPN2209) from Amersham Pharmacia Biotech (Piscataway, NJ). TP53 antibody (catalog no. 9282) and ␤-actin antibody (catalog no. 4967) were purchased from Cell Signaling Technology (Danvers, MA).
